You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Biogen Idec seeks regulatory OK’s for wider use of a multiple sclerosis drug

Biogen Idec Inc. and Elan Corp. said Wednesday that they have asked US and European regulators to approve their Tysabri drug for a wider universe of multiple sclerosis patients.

Because of a possible risk of contracting a rare brain disease that is sometimes fatal, Tysabri is generally recommended for US patients who are not responding to or cannot tolerate an alternative MS therapy.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week